Press Releases

Pfizer Inc. and BioNTech SE today announced that the U.S. government has purchased 50 million more doses of the companies’ COVID-19 vaccine. The U.S. will receive these additional doses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 years of age, should they receive regulatory authorization. The companies expect to deliver all these doses by April 30, 2022. With this order, the U.S. government has exercised its

Eton Pharmaceuticals, Inc , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. marketing rights to carglumic acid tablets. The product’s Abbreviated New Drug Application, which is owned by Novitium Pharma, was approved by the U.S. Food and Drug Administration on October 13, 2021. The product is an AB-rated, substitutable generic version of Carbaglu®. “We are

Waters Corporation and Sartorius announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development. Sartorius and Waters will partner to implement the BioAccord™ LC-MS System from Waters as a new bioprocess analyzer with data connectivity to Sartorius’ Ambr® multi-parallel bioreactor systems to deliver mass spectral information

Amneal Pharmaceuticals, Inc. today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethasone, the generic version of Decadron®, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19. “Today’s approval and launch of dexametha

Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical research technology solutions, announced today the launch of Site IQ™ to enable faster study startup. The platform builds on Advarra's deep experience as the market leading IRB and leading provider of practice management solutions for clinical research, serving all of the top US research institutions, including the most renowned NCI-designated cancer centers, t

Angel Pharmaceuticals Co., Ltd. announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in patients with relapsed/refractory T-cell lymphomas (TCL) in China. CPI-818, the first-and-only ITK inhibitor in clinical development, has been shown to selectively inhibit ITK (interleukin-2-inducible T-cell kinase) without effect on related kinases such as RLK (resting lymphocyte kina

The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The analysis foresees the use of automated cobots, AI, real-time release and rapid growth in new areas like mRNA vaccines, alongside the personalization of therapeutics (delivered at far larger scale). In terms of geographic dominance, value in the pharma market will be led by the USA and China [accounting for around 50%], followed by European nations

HCmed Innovations (HCmed), a Taiwanese company that focuses on the development of vibrating mesh nebulizers, today announced the successful completion of the first developmental milestone for the collaboration agreement with CSL Behring. Earlier this year, global biotherapeutics leader CSL Behring partnered with HCmed to develop a combination product consisting of a plasma-derived immunoglobulin formulation (CSL787) administered via a customized version of the AdheResp nebulizer, HC

Oncodesign , a French biopharmaceutical company specialized in kinase inhibitor research and precision medicine, and TiumBio , a company specializing in R&D for rare diseases, have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis. Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while Tium

Small Pharma Inc. a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its successful upgrade from the OTC Pink to the OTCQB® Venture Market , a United States trading platform that is operated by the OTC Markets Group Inc. in New York. The common shares of the Company will continue to trade on the TSX Venture Exchange (the “TSXV”) under the symbol “DMT”. The Company has also received Depository Trust Company (“DTC&rd